Scarica l'app Stockscreener
1.75
1.74%
0.03
Dopo l'orario di chiusura:
1.75
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Rating of “Hold” by Brokerages - Defense World
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Yahoo Finance
Jasper Therapeutics to Present at Upcoming Investor Conferences - Sahm
Jasper Therapeutics, Inc. (NASDAQ: JSPR) Investor Alert: Deadline in Lawsuit on November 18, 2025 - openPR.com
DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Markets Financial Content
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit - Business Wire
Portnoy Law Firm Announces Class Action on Behalf of Jasper Therapeutics, Inc. Investors - GlobeNewswire
JSPR DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Jasper Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, - GlobeNewswire
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
JSPR DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Jasper Therapeutics, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages - GlobeNewswire
JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors ... - Bluefield Daily Telegraph
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
Bank of Montreal Can Has $878,000 Stock Position in Jasper Therapeutics, Inc. $JSPR - Defense World
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper - MarketScreener
William Blair Has Negative Outlook of JSPR FY2025 Earnings - Defense World
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Th - GuruFocus
JSPR Deadline: JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
JSPR Shareholders Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
International Business Times - Markets Financial Content
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025JSPR - MarketScreener
Jasper Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsJSPR - Stock Titan
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - MarketScreener
JSPR DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR RIGHTS - GlobeNewswire
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RBC Capital Maintains Jasper Therapeutics (JSPR) Sector Perform Recommendation - Nasdaq
Jasper Therapeutics stock price target lowered to $4 at RBC on BEACON concerns - Investing.com Canada
A look into Jasper Therapeutics Inc (JSPR)’s deeper side - Setenews
JSPR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Jasper Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Get in on Rani Therapeutics Holdings Inc’s (RANI) buy-in window today! - setenews.com
RBC Cuts Price Target on Jasper Therapeutics to $4 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Jasper Therapeutics Reports Q3 2025 Financial Results - TipRanks
JSPR DEADLINE ALERT: ROSEN, A TOP-RANKED LAW FIRM, - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights - GlobeNewswire
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) - GlobeNewswire
DEADLINE ALERT for CYTK, NX, JSPR, and KBR: The Law Offices - GlobeNewswire
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
Jasper Therapeutics reports Q3 EPS ($1.13), consensus ($1.29) - TipRanks
Jasper Therapeutics, Inc. SEC 10-Q Report - TradingView
[10-Q] Jasper Therapeutics, Inc. Quarterly Earnings Report | JSPR SEC FilingForm 10-Q - Stock Titan
Jasper Therapeutics Q3 loss smaller than estimates - MarketScreener
[8-K] Jasper Therapeutics, Inc. Reports Material Event | JSPR SEC FilingForm 8-K - Stock Titan
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
Jasper Therapeutics Faces Legal Storm Amid Clinical Trial Setbacks - Ad-hoc-news.de
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):